ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "Metastatic Hormone-Sensitive Prostate Cancer: Extending Life By Adding a Third Drug to Standard Regimens with Dr. Vincent Khoo"
Episode Synopsis
In this edition of OncTimes Talk we’re taking a look at: extending life in patients with metastatic hormone-sensitive prostate cancer by adding a third drug to standard two-drug regimens.
In the randomized Phase III ARASENS trial—just published in the New England Journal of Medicine—the androgen receptor inhibitor, darolutamide, was compared with placebo when added to gold-standard two-drug therapy.
Peter Goodwin visited the Royal Marsden Hospital in London UK to meet one of the ARASENS study investigators: Consultant Clinical Oncologist Vincent Khoo.
In the randomized Phase III ARASENS trial—just published in the New England Journal of Medicine—the androgen receptor inhibitor, darolutamide, was compared with placebo when added to gold-standard two-drug therapy.
Peter Goodwin visited the Royal Marsden Hospital in London UK to meet one of the ARASENS study investigators: Consultant Clinical Oncologist Vincent Khoo.
In God we trust